Search results
Your search for Emollin returned no results
Showing 1 to 15 of 21 results for emollient
Showing 1 to 15 of 21 results for emollient
This guideline covers diagnosing and managing atopic eczema in children under 12. It aims to improve care for children with atopic eczema by making detailed recommendations on treatment and specialist referral. The guideline also explains how healthcare professionals should assess the effect eczema has on quality of life, in addition to its physical severity.
This guideline sets out an antimicrobial prescribing strategy for secondary bacterial infection of eczema and covers infection of other common skin conditions. It aims to optimise antibiotic use and reduce antibiotic resistance. The recommendations are for adults, young people and children aged 72 hours and over. They do not cover diagnosis.
This quality standard covers diagnosing and managing atopic eczema in children under 12. It describes high-quality care in priority areas for improvement.
View quality statements for QS44Show all sections
Sections for QS44
- Quality statements
- Quality statement 1: Assessment at diagnosis
- Quality statement 2: Stepped approach to management
- Quality statement 3: Psychological wellbeing and quality of life
- Quality statement 4: Provision of emollients
- Quality statement 5: Referral for specialist dermatological advice
- Quality statement 6: Specialist allergy investigation
- Quality statement 7: Treatment of eczema herpeticum
Capecitabine for the treatment of advanced gastric cancer (TA191)
Evidence-based recommendations on capecitabine for treating advanced gastric cancer in adults.
The Debrisoft monofilament debridement pad for use in acute or chronic wounds (MTG17)
Evidence-based recommendations on the Debrisoft monofilament debridement pad for use in acute or chronic wounds.
Healthcare-associated infections: prevention and control in primary and community care (CG139)
This guideline covers preventing and controlling healthcare-associated infections in children, young people and adults in primary and community care settings. It provides a blueprint for the infection prevention and control precautions that should be applied by everyone involved in delivering NHS care and treatment.
Evidence-based recommendations on automated ankle brachial pressure index measurement devices to detect peripheral arterial disease in people with leg ulcers
This guideline covers assessing and managing psoriasis in adults, young people and children. It aims to improve long-term disease control and quality of life for people with psoriasis.
View recommendations for CG153Show all sections
Frequency of application of topical corticosteroids for atopic eczema (TA81)
Evidence-based recommendations on using topical corticosteroids for people with atopic eczema.
Evidence-based recommendations on tacrolimus (Protopic) and pimecrolimus (Elidel) for people with atopic eczema.
Dupilumab for treating moderate to severe atopic dermatitis (TA534)
Evidence-based recommendations on dupilumab (Dupixent) for treating moderate to severe atopic dermatitis in adults.
Grenz rays therapy for inflammatory skin conditions (IPG236)
Evidence-based recommendations on Grenz rays therapy for inflammatory skin conditions. This involves exposing the skin to low-energy, non-penetrative electromagnetic radiation.
View recommendations for IPG236Show all sections
Difelikefalin for treating pruritus in people having haemodialysis (TA890)
Evidence-based recommendations on difelikefalin (Kapruvia) for pruritus in adults with chronic kidney disease having haemodialysis.
Summary of the evidence on topical timolol for treating infantile haemangioma (strawberry marks) to inform local NHS planning and decision-making
Dupilumab for treating moderate to severe prurigo nodularis (TA955)
Evidence-based recommendations on dupilumab (Dupixent) for treating moderate to severe prurigo nodularis in adults when systemic treatment is suitable.